February 2012

he SYNTAX trial cracked open the door for the use of PCI as a treatment option for select patients with complex coronary artery disease. Since the trials enrollment closed, refinements in technologies and techniques continue to nudge the door wider for PCI at the same time that longer-term data from SYNTAX shine favorably on CABG for higher-risk patients. But the verdict is still out on how best to treat patients with multivessel or left main disease if they are not clear-cut candidates for either procedure.

Technology doesn't hold a monopoly on innovation. Innovation can arise in the form of new processes or even in new ways of thinking.

As more cardiovascular practices integrate with hospitals to save on overhead, data management challenges exacerbate the arduous process. Many have to overcome several hurdles to create an almost seamless system.

If a hospital or practices priority is to make money, then it may want to think twice about instituting a transradial PCI program. But if it wants to lower costs, free up resources and be positioned for a shift in reimbursement toward outpatient care and quality incentives, then developing expertise in transradial access will pay dividends, proponents of the procedure say.

Clinical registries allow for benchmarking of one provider to another, linking measurement to performance improvement and leading to the betterment of overall quality of care. However, the cost of participation to individual providers may be a drawback.

In order to provide quality cardiovascular care and continue to make headway in improving outcomes, it is necessary to develop middle-ground policy positions related to the future design of more sustainable Medicare and Medicaid programs.

Select an Issue
""